| Popis: |
Abdullah Mussarat, Muhammad Saqlain Mustafa, Syed Talal Azam, Muhammad Musab Nafees uddin, Rana Muhammad Umer Nasrullah, Mohammad Arham Siddiq Department of Medicine, Jinnah Sindh Medical University, Karachi, PakistanCorrespondence: Mohammad Arham Siddiq, Department of Medicine, Jinnah Sindh Medical University, Iqbal Shaheed Road, Karachi, Pakistan, Tel +923412127759, Email arhammusani99@gmail.comAbstract: Glabellar frown lines, also known as worry lines, are a common sign of aging. The current treatment option for glabellar lines is subjective and ranges from economical anti-wrinkle creams and skin resurfacing techniques such as microdermabrasion and fillers to highly expensive facelifts. Botox® has been the mainstream treatment for decades, but the suggested time between treatments for most toxins is 12– 16 weeks, and evidence shows that patients being treated for glabellar lines want longer-lasting results. Recently, on September 16th, the US Food and Drug Administration (FDA) approved the development of daxibotulinumtoxinA (DAXI) for injection based on clinical trials (SAKURA 1, 2, and 3). These encouraging findings followed by FDA approval mean that the need for repeated treatments to sustain the desired outcome has decreased. DAXI could be a reliable and secure choice for reducing the appearance of wrinkles on the face caused by muscle activity, and its long duration has the potential to enhance the treatment of both therapeutic and cosmetic disorders.Keywords: glabellar lines, Botox, daxibotulinumtoxinA, SAKURA, wrinkles |
